Stereotaxis, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 25, 2015, reports the financial results for Stereotaxis, Inc. for the fourth quarter and full year ended December 31, 2014. The company operates in the medical technology sector, focusing on magnetic navigation systems for cardiac procedures.
Key Financial Metrics
| Metric | Q4 2014 | Q4 2013 | Full Year 2014 | Full Year 2013 |
|---|---|---|---|---|
| Total Revenue | $9.8 million | $9.1 million | $35.0 million | $38.0 million |
| Gross Margin | 76.6% ($7.5M) | 68.7% ($6.2M) | 77.0% ($26.8M) | 71.0% ($27.0M) |
| Operating Income/Loss | $0.3 million | ($2.4) million | ($5.4) million | ($8.9) million |
| Net Income/Loss | $0.9 million ($0.04/share) | ($4.0) million ($0.23/share) | ($5.2) million ($0.26/share) | ($68.8) million ($5.95/share) |
| Cash Burn | $1.4 million | $1.4 million | $9.2 million | $6.3 million |
| Cash & Equivalents (Year End) | $7.3 million (Dec 31, 2014) | |||
| Total Debt (Year End) | $18.4 million |
Material Changes
- Revenue Growth: Q4 2014 revenue increased 8% year-over-year, driven by system sales ($3.2M) and recurring revenue ($6.6M). Full-year revenue declined 8% to $35.0 million.
- Profitability Improvement: The company achieved operating income of $0.3 million in Q4 2014, reversing a $2.4 million loss in the prior year quarter. Full-year operating loss improved 39% to $5.4 million.
- Margin Expansion: Gross margins improved significantly in both Q4 (76.6% vs 68.7%) and the full year (77% vs 71%).
- Expense Reduction: Operating expenses decreased 17% in Q4 and 10% for the full year compared to 2013.
- Backlog: Ending capital backlog stood at $5.7 million, with new capital orders of $2.9 million in Q4.
Outlook, Risks, and Unusual Items
- Unusual Items: Q4 2014 net income included a $3.5 million gain from mark-to-market warrant revaluation. Excluding this, the company reported a net loss of $0.5 million. Full-year 2013 results were heavily impacted by $53.9 million in one-time charges related to convertible debt extinguishment.
- Liquidity: Cash and cash equivalents decreased from $13.8 million to $7.3 million during 2014. Cash burn increased 46% for the full year to $9.2 million.
- Debt: Total debt of $18.4 million is attributed to HealthCare Royalty Partners. Interest expense dropped significantly in 2014 ($3.3M) compared to 2013 ($12.6M) due to the prior year's debt extinguishment.
- Forward-Looking Statements: The filing includes standard disclaimers that future performance is subject to risks and uncertainties, and the company does not intend to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the sustainability of the 76.6% gross margin given the mix of system vs. recurring revenue.
- Assess the impact of the $18.4 million debt obligation on future cash flow and interest expenses.
- Confirm the trajectory of cash burn ($9.2M in 2014) against the remaining cash balance of $7.3 million.
- Review the details of the $3.5 million warrant revaluation gain to understand its non-recurring nature.
- Monitor the $5.7 million capital backlog for conversion rates into future revenue.